drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T)
drug_description
Gene-modified autologous T cells expressing a chimeric antigen receptor targeting CD19; infused IV to deplete CD19+ B-lineage cells and reduce autoantibody-driven inflammation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Chimeric Antigen Receptor-Directed
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a CD19-directed chimeric antigen receptor recognize and eliminate CD19+ B-lineage cells (including B cells and plasmablasts), reducing autoantibody production, antigen presentation, and B–T cell costimulation, thereby dampening inflammatory pathways.
drug_name
SWK002 (autologous anti-CD19 CAR-T cells)
nct_id_drug_ref
NCT06503237